Akeso Inc. has announced the enrollment of the first patient in a Phase III clinical trial of ivonescimab for the treatment of metastatic pancreatic cancer. This trial, designated AK112-310/HARMONi-GI2, will investigate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with chemotherapy, with or without ligufalimab, a CD47 monoclonal antibody. The study aims to address the current lack of effective first-line immunotherapy options for metastatic pancreatic cancer, a condition known for its resistance to existing treatments. Co-principal investigators include Professor Yu Xianjun from Fudan University Shanghai Cancer Center, Professor Ying Jie'er from Zhejiang Cancer Hospital, and Professor Tai Sheng from Harbin Medical University Cancer Hospital. The results of this pivotal trial are expected to be presented in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.